Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
106.78%
Net Margin
96.82%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
106.78%
Income Tax Rate
0.00%
EPS
0.5700000000
Balance Sheet Analysis
Current Ratio
0.00
Cash Ratio
0.11
Working Capital
$-39.61M
Debt to Equity
0.12
Debt to Assets
10.14%
Equity Ratio
87.62%
Cash Flow Analysis
Operating Cash Flow Ratio
9.90%
Free Cash Flow Ratio
9.90%
CapEx to Revenue
0.00%
Dividends Paid
$19.79M
Stock Buybacks
No buybacks
Total Shareholder Returns
$19.79M
Cash Position Change
-55.95%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
124.07%
Net Income
123.10%
EPS
122.98%
Operating Income
125.78%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-11.71%
Operating Cash Flow
-88.43%
Free Cash Flow
-88.43%
Balance Sheet Health
Assets
-2.77%
Debt
-36.36%
Book Value per Share
2.48%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-22.53%
Shares Outstanding
0.69%
Long Term Trends
3Y Revenue/Share
-44.33%
5Y Revenue/Share
137.15%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%